CD8A and neoplasm: Moreover, unlike partial blocking of tumor progression or invasive signals, CD40 agonists are “ignition” signals that promote the initiation of immune responses in PDAC, contributing to anti-tumor immunity dependent on CD8 T cells and activated antigen-presenting cells (APCs) [32].